Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'QUETIAPINE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 89 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Wolters, EC; Berendse, HW
      Management of psychosis in Parkinson's disease

      CURRENT OPINION IN NEUROLOGY
    2. Tauscher, J; Kapur, S
      Choosing the right dose of antipsychotics in schizophrenia - Lessons from neuroimaging studies

      CNS DRUGS
    3. Hughes, DA; Walley, T
      Economic evaluations during early (phase II) drug development - A role forclinical trial simulations?

      PHARMACOECONOMICS
    4. Beelen, AP; Yeo, KTJ; Lewis, LD
      Asymptomatic QTc prolongation associated with quetiapine fumarate overdosein a patient being treated with risperidone

      HUMAN & EXPERIMENTAL TOXICOLOGY
    5. Rowsell, R; Link, C; Donoghue, J
      Atypical antipsychotics in the treatment of schizophrenia - Validity of dropout rates as proxy measure of tolerability is unknown

      BRITISH MEDICAL JOURNAL
    6. Gefvert, O; Lundberg, T; Wieselgren, IM; Bergstrom, M; Langstrom, B; Wiesel, FA; Lindstrom, L
      D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    7. Sharma, T
      Quetiapine - efficacy in different domains

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    8. Kasper, S; Tauscher, J; Heiden, A
      Quetiapine: efficacy and tolerability in schizophrenia

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    9. Lynch, J; Morrison, J; Graves, N; Meddis, D; Drummond, MF; Hellewell, JSE
      The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia

      EUROPEAN PSYCHIATRY
    10. Sa, DS; Kapur, S; Lang, AE
      Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis

      CLINICAL NEUROPHARMACOLOGY
    11. DeVane, CL; Nemeroff, CB
      Clinical pharmacokinetics of quetiapine - An atypical antipsychotic

      CLINICAL PHARMACOKINETICS
    12. Binder, EB; Kinkead, B; Owens, MJ; Kilts, CD; Nemeroff, CB
      Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating

      JOURNAL OF NEUROSCIENCE
    13. Sarkar, J; Jones, N; Sullivan, G
      A case of depersonalization-derealization syndrome during treatment with quetiapine

      JOURNAL OF PSYCHOPHARMACOLOGY
    14. Mir, S; Taylor, D
      Atypical antipsychotics and hyperglycaemia

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    15. Wirshing, DA
      Adverse effects of atypical antipsychotics

      JOURNAL OF CLINICAL PSYCHIATRY
    16. Mullen, J; Jibson, MD; Sweitzer, D
      A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study

      CLINICAL THERAPEUTICS
    17. Bymaster, FP; Falcone, JF; Bauzon, D; Kennedy, JS; Schenck, K; DeLapp, NW; Cohen, ML
      Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    18. Woods, SW; Stolar, M; Sernyak, MJ; Charney, DS
      Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

      BIOLOGICAL PSYCHIATRY
    19. Ruhe, HG; Becker, HE; Jessurun, P; Marees, CH; Heeringa, M; Vermeulen, HDB
      Agranulocytosis and granulocytopenia associated with quetiapine

      ACTA PSYCHIATRICA SCANDINAVICA
    20. Jones, HM; Travis, MJ; Mulligan, R; Bressan, RA; Visvikis, D; Gacinovic, S; Ell, PJ; Pilowsky, LS
      In vivo 5-HT2A receptor blockade by quetiapine - An R91150 single photon emission tomography study

      PSYCHOPHARMACOLOGY
    21. Brecher, M; Rak, IW; Melvin, K; Jones, AM
      The long-term effect of quetiapine (Seroquel (TM)) monotherapy on weight in patients with schizophrenia

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    22. Reznik, I; Benatov, R; Sirota, P
      Long-term efficacy and safety of quetiapine in treatment-refractory schizophrenia: A case report

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    23. Matheson, AJ; Lamb, HM
      Quetiapine - A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease

      CNS DRUGS
    24. Khouzam, HR
      Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine

      DEPRESSION AND ANXIETY
    25. Worrel, JA; Marken, PA; Beckman, SE; Ruehter, VL
      Atypical antipsychotic agents: A critical review

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    26. Feret, BM; Caley, CF
      Possible hypothyroidism associated with quetiapine

      ANNALS OF PHARMACOTHERAPY
    27. Shelton, PS; Barnett, FL; Krick, SE
      Hyperventilation associated with quetiapine

      ANNALS OF PHARMACOTHERAPY
    28. Davidson, M; Weiser, M; Soares, K
      Novel antipsychotics in the treatment of psychosis and aggression associated with dementia: A meta-analysis of randomized controlled clinical trials

      INTERNATIONAL PSYCHOGERIATRICS
    29. Carriere, P; Bonhomme, D; Lemperiere, T
      Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)

      EUROPEAN PSYCHIATRY
    30. Balestrieri, M; Vampini, C; Bellantuono, C
      Efficacy and safety of novel antipsychotics: A critical review

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    31. Thyrum, PT; Wong, YWJ; Yeh, C
      Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    32. Bogan, AM; Shellhorn, E; Brown, ES; Mcdanald, C; Suppes, T
      Switching outpatients between atypical antipsychotics

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    33. Emsley, RA; Raniwalla, J; Bailey, PJ; Jones, AM
      A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    34. Vesely, C; Kufferle, B; Brucke, T; Kasper, S
      Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    35. Peuskens, J
      Switching approach in the management of schizophrenia patients

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    36. Guan, HJ; Dai, J; Zhu, XZ
      Atypical antipsychotic effects of quetiapine fumarate in animal models

      ACTA PHARMACOLOGICA SINICA
    37. Barzega, G; Bogetto, F; Maina, G; Ravizza, L
      Quetiapine in schizophrenic patients: A high- and low-dose double-blind comparison

      EUROPEAN JOURNAL OF PSYCHIATRY
    38. McConville, BJ; Arvanitis, LA; Thyrum, PT; Yeh, C; Wilkinson, LA; Chaney, RO; Foster, KD; Sorter, MT; Friedman, LM; Brown, KL; Heubi, JE
      Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    39. Garver, DL
      Review of quetiapine side effects

      JOURNAL OF CLINICAL PSYCHIATRY
    40. Feifel, D
      Rationale and guidelines for the inpatient treatment of acute psychosis

      JOURNAL OF CLINICAL PSYCHIATRY
    41. Tariot, PN; Salzman, C; Yeung, PP; Pultz, J; Rak, IW
      Long-term use of quetiapine in elderly patients with psychotic disorders

      CLINICAL THERAPEUTICS
    42. Dev, V; Raniwalla, J
      Quetiapine - A review of its safety in the management of schizophrenia

      DRUG SAFETY
    43. Yeung, PP; Tariot, PN; Schneider, LS; Salzman, C; Rak, IW
      Quetiapine for elderly patients with psychotic disorders

      PSYCHIATRIC ANNALS
    44. Chakhava, VO
      Seroquel in patients with schizophrenia

      ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA
    45. Keltner, NL; Coffeen, H; Johnson, JE
      Atypical antipsychotic drugs: Part II

      PERSPECTIVES IN PSYCHIATRIC CARE
    46. Richard, IH; Nutt, J
      Worsening of motor function in Parkinson's disease - A "typical" response to "atypical" antipsychotic medications

      NEUROLOGY
    47. Lambert, M; Moritz, S; Haasen, C; Naber, D
      Conversion from conventional to atypical neuroleptics - recommendations for inpatient and outpatient treatment

      NERVENARZT
    48. Schulz, SC
      New antipsychotic medications: More than old wine and new bottles

      BULLETIN OF THE MENNINGER CLINIC
    49. Taylor, DM; McAskill, R
      Atypical antipsychotics and weight gain - a systematic review

      ACTA PSYCHIATRICA SCANDINAVICA
    50. Vanhauwe, JFM; Ercken, M; van de Wiel, D; Jurzak, M; Leysen, JE
      Effects of recent and reference antipsychotic agents at human dopamine D-2and D-3 receptor signaling in Chinese hamster ovary cells

      PSYCHOPHARMACOLOGY
    51. Porter, JH; Varvel, SA; Vann, RE; Philibin, SD; Wise, LE
      Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats

      PSYCHOPHARMACOLOGY
    52. Remington, G; Kapur, S
      Atypical antipsychotics: are some more atypical than others?

      PSYCHOPHARMACOLOGY
    53. Duncan, GE; Zorn, S; Lieberman, JA
      Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

      MOLECULAR PSYCHIATRY
    54. Canales, PL; Olsen, J; Miller, AL; Crismon, ML
      Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia

      CNS DRUGS
    55. Prior, TI; Chue, PS; Tibbo, P; Baker, GB
      Drug metabolism and atypical antipsychotics

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    56. Stip, E; Lussier, I; Ngan, E; Mendrek, A; Liddle, P
      Discriminant cognitive factors in responder and non-responder patients with schizophrenia

      EUROPEAN PSYCHIATRY
    57. Leucht, S; Pitschel-Walz, G; Abraham, D; Kissling, W
      Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

      SCHIZOPHRENIA RESEARCH
    58. Keck, PE; McElroy, SL; Strakowski, SM
      Schizoaffective disorder: role of atypical antipsychotics

      SCHIZOPHRENIA RESEARCH
    59. Volavka, J; Citrome, L
      Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns

      SCHIZOPHRENIA RESEARCH
    60. Purdon, SE
      Cognitive improvement in schizophrenia with novel antipsychotic medications

      SCHIZOPHRENIA RESEARCH
    61. Dickson, RA; Glazer, WM
      Neuroleptic-induced hyperprolactinemia

      SCHIZOPHRENIA RESEARCH
    62. Fernandez, HH; Friedman, JH; Jacques, C; Rosenfeld, M
      Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

      MOVEMENT DISORDERS
    63. Hustey, FM
      Acute quetiapine poisoning

      JOURNAL OF EMERGENCY MEDICINE
    64. Davis, PC; Wong, J; Gefvert, O
      Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    65. Dawkins, K; Lieberman, JA; Lebowitz, BD; Hsiao, JK
      Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998

      SCHIZOPHRENIA BULLETIN
    66. Campbell, M; Young, PI; Bateman, DN; Smith, JM; Thomas, SHL
      The use of atypical antipsychotics in the management of schizophrenia

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    67. Green, B
      Focus on quetiapine

      CURRENT MEDICAL RESEARCH AND OPINION
    68. Fleischhacker, WW; Hummer, M
      Do phase III trials have clinical value?

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    69. McManus, DQ; Arvanitis, LA; Kowalcyk, BB
      Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    70. Coley, KC; Carter, CS; DaPos, SV; Maxwell, R; Wilson, JW; Branch, RA
      Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol

      JOURNAL OF CLINICAL PSYCHIATRY
    71. Tariot, PN
      Treatment of agitation in dementia

      JOURNAL OF CLINICAL PSYCHIATRY
    72. Tandon, R; Milner, K; Jibson, MD
      Antipsychotics from theory to practice: Integrating clinical and basic data

      JOURNAL OF CLINICAL PSYCHIATRY
    73. Juncos, JL
      Management of psychotic aspects of Parkinson's disease

      JOURNAL OF CLINICAL PSYCHIATRY
    74. Kasper, S
      First-episode schizophrenia: The importance of early intervention and subjective tolerability

      JOURNAL OF CLINICAL PSYCHIATRY
    75. Gerlach, J
      The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment

      JOURNAL OF CLINICAL PSYCHIATRY
    76. Tariot, PN
      The older patient: The ongoing challenge of efficacy and tolerability

      JOURNAL OF CLINICAL PSYCHIATRY
    77. Elliott, J; Reynolds, GP
      Agonist-stimulated GTP gamma[S-35] binding to 5-HT1A receptors in human post-mortem brain

      EUROPEAN JOURNAL OF PHARMACOLOGY
    78. HAGBERG G; GEFVERT O; BERGSTROM M; WIESELGREN IM; LINDSTROM L; WIESEL FA; LANGSTROM B
      N-[C-11]METHYLSPIPERONE PET, IN CONTRAST TO [C-11] RACLOPRIDE, FAILS TO DETECT D-2 RECEPTOR OCCUPANCY BY AN ATYPICAL NEUROLEPTIC

      PSYCHIATRY RESEARCH-NEUROIMAGING
    79. KING DJ
      QUETIAPINE - RESULTS OF 4 PHASE-II AND PHASE-III CLINICAL-TRIALS

      European psychiatry
    80. HONG WW; RAK IW; CIURYLA VT; WILSON AM; KYLSTRA JW; MELTZER HY; CARPENTER WT; LEHMAN A; ARVANITIS LA
      MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION

      Schizophrenia research
    81. GOREN JL; LEVIN GM
      QUETIAPINE, AN ATYPICAL ANTIPSYCHOTIC

      Pharmacotherapy
    82. BARNES TRE; MCPHILLIPS MA
      NOVEL ANTIPSYCHOTICS, EXTRAPYRAMIDAL SIDE-EFFECTS AND TARDIVE-DYSKINESIA

      International clinical psychopharmacology
    83. MELTZER HY; CASEY DE; GARVER DL; LASAGNA L; MARDER SR; MASAND PS; MILLER D; PICKAR D; TANDON R
      CLINICAL DEVELOPMENT OF ATYPICAL ANTIPSYCHOTICS - RESEARCH DESIGN ANDEVALUATION

      The Journal of clinical psychiatry
    84. KING DJ; LINK CGG; KOWALCYK B
      A COMPARISON OF BD AND TID DOSE REGIMENS OF QUETIAPINE (SEROQUEL) IN THE TREATMENT OF SCHIZOPHRENIA

      Psychopharmacology
    85. GEFVERT O; BERGSTROM M; LANGSTROM B; LUNDBERG T; LINDSTROM L; YATES R
      TIME-COURSE OF CENTRAL NERVOUS DOPAMINE-D-2 AND 5-HT2 RECEPTOR BLOCKADE AND PLASMA DRUG CONCENTRATIONS AFTER DISCONTINUATION OF QUETIAPINE (SEROQUEL(R)) IN PATIENTS WITH SCHIZOPHRENIA

      Psychopharmacology
    86. ARVANITIS LA; MILLER BG; BORISON RL; PITTS WM; SHARIF ZA; HAMNER MB; HERZ MI; TRUE JE; VELLIGAN D; KNESEVICH MA; SMALL J; STEINBOOK R; HERTZMAN M; KECK PE; NEWCOMER JW; GRACE J; ROTROSEN J; TANDON R; DOTT SG; FERGUSON JM; ADDINGTON DEN; MACEWAN GW; NAIR VNP; SHRIQUI CL; WILLIAMS R; DANIEL DG; SHEHI GM; PATTERSON WM; MERIDETH CH
      MULTIPLE FIXED DOSES OF SEROQUEL (QUETIAPINE) IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA - A COMPARISON WITH HALOPERIDOL AND PLACEBO

      Biological psychiatry
    87. PEUSKENS J; LINK CGG
      A COMPARISON OF QUETIAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA

      Acta psychiatrica Scandinavica
    88. KUFFERLE B; TAUSCHER J; ASENBAUM S; VESELY C; PODREKA I; BRUCKE T; KASPER S
      IBZM SPECT IMAGING OF STRIATAL DOPAMINE-2 RECEPTORS IN PSYCHOTIC-PATIENTS TREATED WITH THE NOVEL ANTIPSYCHOTIC SUBSTANCE QUETIAPINE IN COMPARISON TO CLOZAPINE AND HALOPERIDOL

      Psychopharmacology
    89. TAUSCHER J; KUFFERLE B; ASENBAUM S; BRUCKE T; KASPER S
      PREVIOUS TREATMENT AS A CONFOUNDING VARIABLE IN STUDIES WITH NOVEL ANTIPSYCHOTICS - 2 CASES OF HIGH DOPAMINE-2 RECEPTOR OCCUPANCY WITH QUETIAPINE

      Psychopharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/10/19 alle ore 04:07:06